We know from the randomised controlled trials from the UK, Denmark and West Australia that screening elderly men for abdominal aortic aneurysm with ultrasound saves lives and is cost-effective. According to the latest results from the British MASS trial, screening decreases all-cause mortality by 3% (95% confidence intervals, 1–5%) in the overall screened population—an extraordinary result. These results are the rationale behind the establishment of national screening programmes for 65-year-old men in England and Sweden, and the US Medicare and the Society for Vascular Surgery recommendation of aneurysm screening of men and smoking women.
As our understanding of dissection grows, the fate of the false lumen through the progression of disease is becoming a more important variable that predicts outcome, writes Tara Mastracci. If stenting is performed in the acute or subacute phase, in a majority of patients, the false lumen will thrombose to the level of the stent, or beyond, promoting aortic remodelling and thus decreasing the need for further intervention. However, in that subset of patients in whom the false lumen remains perfused or pressurised, aneurysmal degeneration occurs and the risk of rupture and death remains a persistent threat.
A recent comparison of in-hospital mortality following rupture of an abdominal aortic aneurysm in England and the USA suggests that too few patients in England are being selected for aneurysm repair, too few are treated in high-volume centres and too few are offered endovascular (EVAR) versus open repair, writes Michael Sweeting.
Prakash Krishnan, Mount Sinai Medical Center, New York, USA, presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons (NCVH) annual conference (1–3 June, New Orleans, USA). The ILLUMENATE Global Study is a prospective, multicentre, single-arm study designed to assess the clinical performance of the Stellarex drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
Medtronic and the University of Texas Health Science Center at Houston (UTHealth) have announced the first patient enrolled in a clinical study assessing the Medtronic Valiant Evo thoracic stent graft system for the minimally invasive repair of descending thoracic aortic aneurysms (TAA). The international, multicentre, prospective study will include 100 patients in the USA and Europe. The news was reported at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (8–11 June, National Harbor, USA).
VentureMed has announced receipt of US Food and Drug Administration (FDA) 510(k) clearance for the Flex scoring catheter, an endovascular device that precisely and dynamically scores any length of atherosclerotic lesion as it passes through the femoral-popliteal anatomy. Flex received European CE mark approval in 2015.
Lombard Medical has announced positive clinical results from The Prospective Aneurysm Trial: High Angle Aorfix Bifurcated Stent Graft (PYTHAGORAS trial) at the 2016 Society for Vascular Surgery Annual Meeting in National Harbor, USA.
Results from Veryan’s Mimics randomised controlled trial have been published in the latest issue of Circulation: Cardiovascular Interventions. Use of the BioMimics 3D helical stent resulted in higher patency at two years when compared with a straight stent, for the treatment of symptomatic disease of the superficial femoral and popliteal arteries.
Six presentations on Silk Road Medical’s Enroute transcarotid neuroprotection and stent system were given at the Society for Vascular Surgery annual meeting (8–11 June, National Harbor, USA).
Gore has announced that its TAG thoracic device family has exceeded 100,000 devices distributed worldwide.
Enrolment into Gore’s early feasibility study evaluating the Excluder thoracoabdominal branch endoprosthesis (TAMBE) for the treatment of aortic aneurysms involving the visceral branch vessels has now been completed. The TAMBE is designed to be the first complete off-the-shelf solution for the treatment of this complex disease.
Intact Vascular has announced that its Tack Optimised Balloon Angioplasty III (TOBA III) clinical trial has commenced enrolment, with the first patient treated by Klaus Brechtel at the Franziskus-Hospital in Berlin, Germany.
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations are aimed at ensuring that medical devices and in vitro diagnostic medical devices are safe while allowing patients to benefit from innovative health care solutions in a timely manner. However, the agreement is subject to the approval by the Council’s Permanent Representatives Committee and of the Parliament’s ENVI committee.
Cardionovum has announced the completion of enrolment of the RAPID trial, which is investigating the safety and effectiveness of the company’s Legflow drug-coated balloon.
OrbusNeich has expanded its portfolio to include products to treat peripheral artery disease. The JADE and Scoreflex PTA balloons are the company’s first entry devices for lower limb and arteriovenous fistula intervention.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos